KAPA: ENV105 shows promise in overcoming cancer drug resistance, with pivotal trial data expected by 2026
ENV105, an antibody targeting CD105, is advancing in phase I/II trials for prostate and lung cancer, showing strong early efficacy and safety. Strategic collaborations, robust funding, and a multi-center academic consortium support rapid development, with key interim data expected by 2026.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.